US-based Physicians Hearing Network (PHN) is implementing a cognitive assessment platform developed by BrainCheck into its standard hearing care service provision.

With more than 270 member providers spread across 12 US states, hearing aid services provider PHN has said the move would enable its network physicians to offer complimentary cognitive screening alongside hearing tests.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

“I’m excited for our patients and the physicians we partner with because we’re solving an unmet need by providing screening for both hearing and cognition in the convenient setting of their physician’s office,” said PHN CEO William McCrae.

BrainCheck is the developer of a digital platform designed to help physicians check the cognitive health of patients and determine if further testing may be needed.

The company’s standard test battery, Assess, is a US Food and Drug Administration (FDA) Class II medical device that detects signs of cognitive impairment through a suite of memory tests, neuropsychological tests around attention, and its Digit-Symbol Substitution test to assess executive function.

BrainCheck Assess has been clinically proven to offer accuracy on par with traditional tests, such as the Saint Louis University Mental Status (SLUMS) exam, Mini-Mental Status Exam (MMSE), and Montreal Cognitive Assessment (MoCA)

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

In addition, BrainCheck’s Plan helps clinicians build, document, and deliver care plans for patients with cognitive decline, post-diagnosis.

A 2023 study by the Johns Hopkins Bloomberg School of Public Health found that older adults with greater severity of hearing loss were more likely to have dementia, but the likelihood of dementia was lower among hearing aid users compared to non-users.

The study also found that for adults at increased risk of cognitive decline, hearing loss intervention slowed down loss of thinking and memory abilities by 48% over three years.

In March 2024, BrainCheck concluded a $15m venture funding raise. Led by Next Coast Ventures, S3 Ventures, and UPMC Enterprises, BrainCheck said the funding would help it accelerate its commercial traction and expand innovation within its product portfolio.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact